# Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease

> **NIH NIH N01** · TULANE UNIVERSITY OF LOUISIANA · 2022 · $1,274,999

## Abstract

The Contractor is developing Burkholderia-derived outer membrane vesicles (OMVs), containing a naturally-attenuated lipid A, as a vaccine adjuvant.  This research will develop the adjuvant within the context of a vaccine to prevent Lyme disease in humans.  Borrelia burgdorferi is the etiologic agent of Lyme disease, which is transmitted by the bite of Ixodes ticks. There are no currently approved vaccines that prevent Lyme disease in humans.

## Key facts

- **NIH application ID:** 10672571
- **Project number:** 272201800045C-P00009-9999-2
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **Principal Investigator:** LISA MORICI
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,274,999
- **Award type:** —
- **Project period:** 2018-09-30 → 2023-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10672571

## Citation

> US National Institutes of Health, RePORTER application 10672571, Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease (272201800045C-P00009-9999-2). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10672571. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*